KMO and breast carcinoma: First, the upregulation of KMO can suppress the antitumor immune responses in patients with breast cancers [44,45], and second, with an elevated KMO expression, the activation of the kynurenine pathway, via STAT3 and pSTAT3, potentially promotes the development of tumors into more aggressive phenotypes.